



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January - March 2010

Sefton DAT

Quarter 4 2009/10

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Ellie McCoy and Paul Duffy.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
4th Floor, Kingsway House
Hatton Gardens
Liverpool
L3 2AY

(0151) 904 6031
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 8014
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Needle and Syringe Programmes (NSPs)	5
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency NSP Clients, by Gender	
Table 13: Main Drug of Use for All Agency NSP Clients, by Gender	
Table 14: Main Drug of Use, for New Agency NSP Clients, by Age Group	
Pharmacy	11
Table 15: Individuals by Gender	
Table 16: Individuals by Gender Steroid Users Omitted	
Table 17: Individuals by Age Group	
Table 18: Year to Date, by Gender & Age Group	
Table 19: Year to Date, by Gender & Age Group Steroid Users Omitted	
Pharmacy 'Pick & Mix'	13
Table 20: Individuals by Gender	
Table 21: Main Drug of Use for All 'Pick and Mix' Clients by Gender	
Table 22: Year to Date, by Gender & Age Group	
Table 23: Year to Date, by Gender & Age Group Steroid Users Omitted	
Combined	15
Table 24: Individuals in NSP, by Gender	
Table 25: Individuals in NSP, by Gender: Steroid Users omitted	
Table 26: Individuals in NSP, by Age Group	
Table 27: Individuals in NSP, by Age Group: Steroid	

Users omitted

Table 28: Year to Date, by Gender & Age Group

Table 29: Total Syringes Provided

National Drug Treatment Monitoring System (NDTMS) 17

Table 30: Individuals in contact with Treatment Services, by Gender

Table 31: Year to Date, by Gender

Table 32: Individuals in contact with Treatment Services, by Age Group

Table 33: Year to Date, by Age Group

Table 34: Ethnicity of Individuals in Contact with Treatment Services

Table 35: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions 20

Table 36: Individuals in Contact with Connexions, by Gender

Table 37: Year to Date, by Gender

Table 38: Individuals in Contact with Connexions, by Age

Table 39: Year to Date, by Age

Table 40: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 41: Year to Date, by Drug/Alcohol Problem

Combined Datasets 22

Table 42: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 43: Year to Date, by Gender & Age Group

Cross Matched Datasets 23

Fig 1: Crossover between Agency NSP and NDTMS datasets

Fig 2: Crossover between Pharmacy NSP and NDTMS datasets

Fig 3: Crossover between YTD Agency NSP and NDTMS datasets

Fig 4: Crossover between YTD Pharmacy NSP and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)**Quarter 4 (2009/10)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	96	86.5
Female	15	13.5
Age Group		
Under 18	0	0.0
18-19	8	7.2
20-24	27	24.3
25-29	17	15.3
30-34	15	13.5
35-39	18	16.2
40-44	13	11.7
45+	13	11.7
Total	111	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	19	6.3	1	1.9	20	5.6
20-24	72	23.9	13	24.5	85	24.0
25-29	49	16.3	4	7.5	53	15.0
30-34	40	13.3	10	18.9	50	14.1
35-39	56	18.6	8	15.1	64	18.1
40-44	43	14.3	8	15.1	51	14.4
45+	22	7.3	9	17.0	31	8.8
Total	301	100	53	100	354	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	-	-	-
Benzodiazepines	-	-	-
Cannabis	6	1	0
Crack	1	3	0
Cocaine	2	9	41
Ecstasy	-	-	-
Heroin	27	11	4
Methadone	1	0	0
Other	-	-	-

2 individuals did not report their main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2009/10)

Introduction

Data are collected directly from NSP providers. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

Please note that the closure of the Lighthouse Project (LHP) resulted in a severe, but temporary, disruption to the agency-based NSP service. Consequently there is a period within Quarter 2 and Quarter 3 (2009/10) for which we have no data this is reflected in the year to date figures supplied for this quarter. All sites have since re-opened and are supplying monitoring data however the year to date figures may appear lower comparable to Q4 (2008/09) due to LHP closure. Please contact us if you require further information.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	8	100
Female	0	0.0
<i>Total</i>	8	100
All Clients		
Male	36	94.7
Female	2	5.3
<i>Total</i>	38	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	3	100.0
Female	0	0.0
<i>Total</i>	3	100
All Clients		
Male	21	91.3
Female	2	8.7
<i>Total</i>	23	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	4	50.0	6	15.8
25-29	0	0.0	5	13.2
30-34	1	12.5	5	13.2
35-39	1	12.5	9	23.7
40-44	0	0.0	6	15.8
45+	2	25.0	7	18.4
Total	8	100	38	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	33.3	1	4.3
25-29	0	0.0	3	13.0
30-34	0	0.0	2	8.7
35-39	0	0.0	5	21.7
40-44	0	0.0	5	21.7
45+	2	66.7	7	30.4
Total	3	100	23	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	6	16.7	0	0.0
25-29	4	11.1	1	50.0
30-34	4	11.1	1	50.0
35-39	9	25.0	0	0.0
40-44	6	16.7	0	0.0
45+	7	19.4	0	0.0
Total	36	100	2	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	4.8	0	0.0
25-29	2	9.5	1	50.0
30-34	1	4.8	1	50.0
35-39	5	23.8	0	0.0
40-44	5	23.8	0	0.0
45+	7	33.3	0	0.0
Total	21	100	2	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	4	1.2	1	2.6	5	1.4
20-24	54	16.8	4	10.5	58	16.1
25-29	53	16.5	7	18.4	60	16.7
30-34	51	15.8	5	13.2	56	15.6
35-39	63	19.6	8	21.1	71	19.7
40-44	57	17.7	7	18.4	64	17.8
45+	40	12.4	6	15.8	46	12.8
Total	322	100	38	100	360	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	0	0.0	1	2.8	1	<1
20-24	10	5.6	3	8.3	13	6.0
25-29	14	7.8	7	19.4	21	9.8
30-34	32	17.9	5	13.9	37	17.2
35-39	46	25.7	8	22.2	54	25.1
40-44	45	25.1	6	16.7	51	23.7
45+	32	17.9	6	16.7	38	17.7
Total	179	100	36	100	215	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	3	37.5	0	0.0
Methadone	0	0.0	0	0.0
Steroids	5	62.5	0	0.0
Unknown	0	0.0	0	0.0
Total*	8	100	0	0

Table 13: Main Drug of Use for All Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	10	27.8	2	100.0
Methadone	1	2.8	0	0.0
Steroids	15	41.7	0	0.0
Unknown	10	27.7	0	0.0
Total	36	100	2	100

Current Quarter; Melanotan Clients

- 0 New Male clients reported using melanotan during Q4
- 0 New Female clients reported using melanotan during Q4
- 0 Male clients reported using melanotan during Q4
- 0 Female clients reported using melanotan during Q4

Table 14: Main Drug of Use for New Agency NSP Clients, by Age Group

Age Group	Amphetamine		Benzodiazepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
18-19	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
20-24	-	-	-	-	-	-	-	-	1	33.3	-	-	3	60.0
25-29	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
30-34	-	-	-	-	-	-	-	-	0	0.0	-	-	1	20.0
35-39	-	-	-	-	-	-	-	-	0	0.0	-	-	1	20.0
40-44	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
45+	-	-	-	-	-	-	-	-	2	66.7	-	-	0	0.0
Total	-	-	-	-	-	-	-	-	3	100	-	-	5	100

% Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY NSP

Table 15: Individuals by Gender

New Clients	n	%
Male	202	93.5
Female	14	6.5
<i>Total</i>	216	100
All Clients		
Male	460	90.2
Female	50	9.8
<i>Total</i>	510	100

Table 16: Individuals by Gender Steroid Users Omitted*

New Clients	n	%
Male	184	93.4
Female	13	6.6
<i>Total</i>	197	100
All Clients		
Male	431	89.8
Female	49	10.2
<i>Total</i>	480	100

**Main drug of use is known for 'Pick and Mix' Clients Only*

Table 17: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	<1	1	<1
18-19	3	1.4	7	1.4
20-24	27	12.5	46	9.0
25-29	27	12.5	57	11.2
30-34	32	14.8	75	14.7
35-39	36	16.7	88	17.3
40-44	48	22.2	133	26.1
45+	42	19.4	103	20.2
<i>Total</i>	216	100	510	100

Table 18: Year to Date, by Gender & Age Group

Age Group	Gender					
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	3	<1	2	1.2	5	<1
18-19	22	1.7	2	1.2	24	1.6
20-24	128	9.6	7	4.3	135	9.0
25-29	191	14.3	25	15.5	216	14.5
30-34	183	13.7	34	21.1	217	14.5
35-39	261	19.6	36	22.4	297	19.9
40-44	275	20.6	40	24.8	315	21.1
45+	269	20.2	15	9.3	284	19.0
Total	1,332	100	161	100	1,493	100

Table 19: Year to Date, by Gender & Age Group Steroid Users Omitted*

Age Group	Gender					
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	3	<1	2	1.3	5	<1
18-19	22	1.7	2	1.3	24	1.7
20-24	121	9.4	6	3.8	127	8.8
25-29	175	13.7	25	15.7	200	13.9
30-34	175	13.7	34	21.4	209	14.5
35-39	251	19.6	36	22.6	287	19.9
40-44	268	20.9	39	24.5	307	21.3
45+	267	20.8	15	9.4	282	19.6
Total	1,282	100	159	100	1,441	100

*Main drug of use is known for Pick and Mix Clients Only

PHARMACY NSP - SEFTON PICK AND MIX

Data presented here show activity in the pilot 'Pick and Mix' scheme currently operating in selected Sefton pharmacies. This data is also included in the overall pharmacy data provided on page 11 of this report. For further details please contact the IAD

Table 20: Individuals by Gender

New Clients	n	%
Male	40	90.9
Female	4	9.1
<i>Total</i>	44	100
All Clients		
Male	87	92.6
Female	7	7.4
<i>Total</i>	94	100

Table 21: Main Drug of Use for All 'Pick and Mix' Clients by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Crack	4	4.6	1	14.3
Heroin	40	46.0	4	57.1
Steroids	29	33.3	1	14.3
Unknown	13	14.9	1	14.3
<i>Total</i>	87	100	7	100

Table 22: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0.0	1	7.7	1	<1
18-19	0	0.0	0	0.0	0	0.0
20-24	13	8.3	2	15.4	15	8.8
25-29	25	15.9	1	7.7	26	15.3
30-34	22	14.0	0	0.0	22	12.9
35-39	39	24.8	2	15.4	41	24.1
40-44	40	25.5	5	38.5	45	26.5
45+	18	11.5	2	15.4	20	11.8
<i>Total</i>	157	100	13	100	170	100

Table 23: Year to Date, by Gender & Age Group Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	1	9.1	1	<1
18-19	0	0.0	0	0.0	0	0.0
20-24	5	4.8	1	9.1	6	5.2
25-29	8	7.7	1	9.1	9	7.8
30-34	14	13.5	0	0.0	14	12.2
35-39	29	27.9	2	18.2	31	27.0
40-44	33	31.7	4	36.4	37	32.2
45+	15	14.4	2	18.2	17	14.8
Total	104	100	11	100	115	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 24: Individuals in NSP, by Gender

New Clients	n	%
Male	210	93.8
Female	14	6.3
<i>Total</i>	224	100
All Clients		
Male	493	90.6
Female	51	9.4
<i>Total</i>	544	100

Table 25: Individuals in NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	187	93.5
Female	13	6.5
<i>Total</i>	200	100
All Clients		
Male	449	90.0
Female	50	10.0
<i>Total</i>	499	100

*Only known steroid users, based on Agency NSP data and Pharmacy Pick and Mix, have been omitted.

Table 26: Individuals in NSP, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	<1	1	<1
18-19	3	1.3	7	1.3
20-24	31	13.8	52	9.6
25-29	27	12.1	62	11.4
30-34	33	14.7	78	14.3
35-39	37	16.5	96	17.6
40-44	48	21.4	138	25.4
45+	44	19.6	110	20.2
<i>Total</i>	224	100	544	100

Table 27: Individuals in NSP by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	<1	1	<1
18-19	3	1.5	7	1.4
20-24	28	14.0	44	8.8
25-29	19	9.5	49	9.8
30-34	28	14.0	70	14.0
35-39	33	16.5	88	17.6
40-44	45	22.5	131	26.3
45+	43	21.5	109	21.8
Total	200	100	499	100

Table 28: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	<1	2	1.0	5	<1
18-19	26	1.6	3	1.6	29	1.6
20-24	178	11.1	11	5.7	189	10.5
25-29	237	14.7	32	16.6	269	14.9
30-34	229	14.3	37	19.2	266	14.8
35-39	312	19.4	41	21.2	353	19.6
40-44	319	19.9	47	24.4	366	20.3
45+	303	18.9	20	10.4	323	17.9
Total	1,607	100	193	100	1,800	100

Table 29: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	1,625	18,735	20,360	102,744

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS) Quarter 4 (2009/10)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 30: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	151	74.8
Female	51	25.2
<i>Total</i>	202	100
All Clients		
Male	1,384	73.3
Female	504	26.7
<i>Total</i>	1,888	100

Table 31: Year to Date, by Gender

New Clients	n	%
Male	644	77.2
Female	190	22.8
<i>Total</i>	834	100
All Clients		
Male	1,454	73.3
Female	530	26.7
<i>Total</i>	1,984	100

Table 32: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	21	10.4	166	8.8
18-19	8	4.0	40	2.1
20-24	18	8.9	166	8.8
25-29	27	13.4	228	12.1
30-34	24	11.9	331	17.5
35-39	42	20.8	447	23.7
40-44	33	16.3	297	15.7
45+	29	14.4	213	11.3
Total	202	100	1888	100

Table 33: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	106	12.7	176	8.9
18-19	26	3.1	40	2.0
20-24	71	8.5	175	8.8
25-29	101	12.1	236	11.9
30-34	112	13.4	357	18.0
35-39	170	20.4	475	23.9
40-44	144	17.3	307	15.5
45+	104	12.5	218	11.0
Total	834	100	1984	100

Table 34: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	198	98.0	1829	96.9
White Irish	1	<1	6	<1
Other White	1	<1	23	1.2
White & Black Caribbean	0	0.0	3	<1
White & Black African	1	<1	4	<1
African	0	0.0	2	<1
White & Asian	0	0.0	0	0.0
Other Black	0	0.0	3	<1
Other Mixed	0	0.0	4	<1
Other Asian	0	0.0	2	<1
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	1	<1
Other	1	<1	6	<1
Unknown	0	0.0	5	<1
Total	202	100	1888	100

Table 35: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	125	61.9	1132	60.0
Methadone	3	1.5	82	4.3
Other Opiates	1	<1	23	1.2
Benzodiazepine	1	<1	8	<1
Amphetamines	1	<1	13	<1
Cocaine	28	13.9	257	13.6
Crack	9	4.5	56	3.0
Ecstasy	0	0.0	2	<1
Cannabis	34	16.8	285	15.1
Hallucinogens	0	0.0	4	<1
Anti-depressants	0	0.0	1	<1
Prescription Drugs	0	0.0	16	<1
Other/Unknown	0	0.0	9	<1
Total	202	100	1888	100

CONNEXIONS

Quarter 4 (2009/10)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 36: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	67	61.5
Female	42	38.5
Total	109	100

Table 37: Year to Date, by Gender

Gender	n	%
Male	113	64.6
Female	62	35.4
Total	175	100

Table 38: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	36	33.0
17	29	26.6
18	30	27.5
19	14	12.8
Total	109	100

Table 39: Year to Date, by Age

Age Group	n	%
16	55	31.4
17	40	22.9
18	47	26.9
19	33	18.9
Total	175	100

Table 40: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	28	25.7
Drugs	81	74.3
<i>Total</i>	109	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 41: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	47	26.9
Drugs	128	73.1
<i>Total</i>	175	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2009/10)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSP (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 42: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1,905	76.7
Female	578	23.3
Age Group		
Under 18	221	8.9
18-19	90	3.6
20-24	238	9.6
25-29	296	11.9
30-34	402	16.2
35-39	529	21.3
40-44	398	16.0
45+	309	12.4
Total	2,483	100

Table 43: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	188	5.9	72	9.5	260	6.6
18-19	126	4.0	33	4.4	159	4.1
20-24	370	11.7	71	9.4	441	11.2
25-29	441	13.9	91	12.1	532	13.6
30-34	487	15.4	134	17.7	621	15.8
35-39	622	19.6	165	21.9	787	20.1
40-44	505	15.9	116	15.4	621	15.8
45+	431	13.6	73	9.7	504	12.8
Total	3,170	100	755	100	3,925	100

CROSS-MATCHED DATASETS

Quarter 4 (2009/10)

Data are shown for the crossover between each type of NSP and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of NSP site.

Fig 1: Crossover between Agency NSP and NDTMS datasets




Fig 2: Crossover between Pharmacy NSP and NDTMS datasets




Fig 3: Year to Date Crossover between Agency NSP and NDTMS datasets




Fig 4: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

